This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Methodology v4.1
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
Peptide provider directory
Evaluating peptide telehealth providers requires the same rigor as GLP-1 programs, plus honest regulatory disclosure. This directory explains what to look for; we list providers only after verification.
Quick answer
We hold peptide providers to a strict standard: licensed clinician oversight, licensed pharmacy dispensing, honest regulatory status, and no research-chemical sales. Provider listings are added only after verification.
Where should you read next?
Verify a peptide provider
The checklist
Peptide safety
Sourcing and injectable risks
Peptide legality
What 'research use only' means
Research vs prescription
The safety gap
Sources
- U.S. Food and Drug Administration — approval and compounding status.
- Primary clinical literature cited on child pages.
- Our methodology and source standards.
How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.